Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the characteristics and management of adolescent androgenetic alopecia, noting a lack of FDA-approved treatments and reporting no new clinical results.

This study evaluated Korean herbal compounds in silico and identified Biochanin A, Saponin Re, and Emodin as potential topical treatments for androgenetic alopecia, each with specific safety and efficacy considerations.

This study found that 2-hydroxy-1,4-naphthoquinone was the most effective inhibitor of steroid 5α-reductase, showing stronger inhibition than avicequinone C in HaCaT cell assays.

This article describes the efficient synthesis of (S)-N-(2-bromo-6-methoxypyridin-4-yl)-2-hydroxy-2,4-dimethylpentanamide, a novel topical antiandrogen, with high purity and enantiomeric excess but reports no pharmacological results.

AGA is a genetic, hormonal hair loss treated with finasteride, minoxidil, and supplements, but new compounds are being developed.

This study found that among the tested analogs, compound 4e was the most effective in inhibiting wax esters in vivo in the Golden Syrian hamster ear model.

This review covers the pathogenesis, diagnosis, and potential new treatments for androgenetic alopecia but reports no new clinical findings, highlighting an ongoing need for effective therapies.

This study found that several synthesized pregnane derivatives exhibited significant inhibitory effects on testosterone conversion to dihydrotestosterone and reduced related androgenic parameters in multiple pharmacological models.

This review discusses the use of antiandrogens for various conditions like prostate cancer and highlights their potential benefits in remission rates and symptom improvement, but it reports no new clinical results.

In this phase I study, CG2001, a topical foam combining minoxidil and finasteride, was found to be safe and well-tolerated in Chinese males with androgenetic alopecia, showing significantly reduced systemic finasteride exposure compared to oral administration, potentially reducing related side effects.

This study reported unexpected positive results in two males with androgenetic alopecia using a cyclodextrin-enabled, natural-based formula over 270 days, showing marked hair thickening and reduced scalp hair loss.

This study identified LY191704 as a specific noncompetitive inhibitor of human 5 alpha-reductase type 1, which may be useful in treating endocrine disorders related to DHT overproduction.

In this study, lysocellin induced G1 phase arrest in human osteosarcoma cells, but diminished the cytotoxic efficacy of etoposide, while its derivative alopestatin may reduce etoposide-induced alopecia in a rat model.

This study observed that a combination of sinapic acid and glabridin from Zhimo herbal extract improved hair growth and reduced oxidative stress in a DHT-induced model of androgenetic alopecia in mice by preventing ferroptosis and stabilizing β-Catenin, offering potential application for AGA treatment.

This proof-of-concept study suggests that the new topical treatment regimen TH07 may offer effective hair growth results in men with androgenic alopecia, using a combination of finasteride, latanoprost, and minoxidil, supported by animal models and clinical studies.

The new topical product combined with finasteride significantly increased hair thickness without side effects.

This review discusses the increased prevalence of androgenic alopecia in men and women, highlighting the limited FDA-approved treatment options, and reports no clinical results; the authors note adherence challenges due to prolonged drug use.

This review discusses current and emerging treatments for androgenetic alopecia, covering mechanisms, efficacy, and safety of both androgen-targeted and non-androgen-targeted approaches, but reports no new clinical results.

This study found that caffeic acid amide derivative, compound 4, effectively inhibited steroid 5α-reductase type 1 in vitro, suggesting potential for development as a treatment for androgenic alopecia.

This review highlights the potential of nanotechnology in enhancing the treatment of androgenetic alopecia by facilitating targeted drug delivery, improving drug stability, and increasing concentration at target sites, although clinical validation and scalable manufacturing are needed for practical implementation.

This study observed that the compound EM-402 reduced 5α-reductase activity and sebaceous gland size in the flank organs and ears of hamsters, indicating potent localized anti-androgenic effects without systemic action.

This study reported that the topical treatment HDMHG0401-10 significantly improved hair density in men with androgenetic alopecia compared to placebo, although subjective hair growth ratings were not significantly different.

This study developed nanoliposomes embedding AR-PROTAC and NFKBIZ siRNA to target androgen receptors and reduce oxidative stress, which improved the follicular microenvironment and enhanced hair regrowth in androgenetic alopecia, suggesting a promising multi-target therapeutic strategy.

In this study, researchers discovered a compound called C6 that exhibits excellent skin retention and androgen receptor degradation properties, significantly promoting hair regeneration in a mouse model of androgenetic alopecia following non-invasive topical application, suggesting potential for broader use of PROTACs in treating skin diseases.

This abstract outlines a guide reviewing both FDA-approved and off-label therapies for androgenetic alopecia and proposes treatment algorithms based on scientific research, highlighting a gap in common treatments for this prevalent condition.

This review discusses recent advancements in understanding the pathophysiology of androgenetic alopecia and highlights the potential for multilateral topical therapies to improve treatment efficacy with fewer side effects; it reports no new clinical results.

This correspondence discusses clascoterone as a potential new treatment for androgenetic alopecia but reports no clinical results.

This article discusses male androgenetic alopecia, describing its progression and pattern, and reports no new findings or clinical results.

In this study, researchers used an integrated in silico approach to demonstrate that Polygonum multiflorum combats androgenetic alopecia via anthraquinone emodin, which targets PI3K catalytic subunits differently from traditional antiandrogenic treatments, showing potential as a novel therapeutic strategy.